2-Benzylidene-1-indanone derivatives as inhibitors of monoamine oxidase

被引:37
作者
Nel, Magdalena S. [1 ,2 ]
Petzer, Anel [1 ,2 ]
Petzer, Jacobus P. [1 ,2 ]
Legoabe, Lesetja J. [2 ]
机构
[1] North West Univ, Sch Pharm, Pharmaceut Chem, Private Bag X6001, ZA-2520 Potchefstroom, South Africa
[2] North West Univ, Ctr Excellence Pharmaceut Sci, Private Bag X6001, ZA-2520 Potchefstroom, South Africa
基金
新加坡国家研究基金会; 英国医学研究理事会;
关键词
Monoamine oxidase; MAO; Inhibition; Reversible; 2-Benzylidene-1-indanone; MAO-B INHIBITORS; PARKINSONS-DISEASE; REVERSIBLE INHIBITORS; CHALCONES; THERAPY;
D O I
10.1016/j.bmcl.2016.08.067
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In the present study, a series of twenty-two 2-benzylidene-1-indanone derivatives were synthesised and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B. The 2-benzylidene-1-indanone derivatives are structurally related to a series of benzylideneindanone derivatives which has previously been found to be MAO-B inhibitors. This study finds that the 2-benzylidene-1-indanones are MAO-B specific inhibitors with IC50 values <2.74 mu M. Among the compounds evaluated, twelve compounds exhibited IC50 <0.1 mu M and may be considered as high potency inhibitors. The 2-benzylidene-1-indanone derivatives also inhibited MAO-A with the most potent inhibition exhibited by 5g (IC50 = 0.131 mu M). An analysis of the structure-activity relationships for MAO-B inhibition show that substitution on the A-ring with a 5-hydroxy group and on the B-ring with halogens and the methyl group yield high potency inhibition. It may therefore be concluded that 2-benzylidene-1-indanone analogues are promising leads for design of therapies for disorders such as Parkinson's disease. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4599 / 4605
页数:7
相关论文
共 30 条
[1]   Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: Safinamide and coumarin analogs [J].
Binda, Claudia ;
Wang, Jin ;
Pisani, Leonardo ;
Caccia, Carla ;
Carotti, Angelo ;
Salvati, Patricia ;
Edmondson, Dale E. ;
Mattevi, Andrea .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (23) :5848-5852
[2]   Moclobemide: Therapeutic use and clinical studies [J].
Bonnet, U .
CNS DRUG REVIEWS, 2003, 9 (01) :97-140
[3]   Monoamine oxidase inactivation: From pathophysiology to therapeutics [J].
Bortolato, Marco ;
Chen, Kevin ;
Shih, Jean C. .
ADVANCED DRUG DELIVERY REVIEWS, 2008, 60 (13-14) :1527-1533
[4]   New Frontiers in Selective Human MAO-B Inhibitors [J].
Carradori, Simone ;
Silvestri, Romano .
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (17) :6717-6732
[5]   Novel monoamine oxidase inhibitors: a patent review (2012-2014) [J].
Carradori, Simone ;
Petzer, Jacobus P. .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2015, 25 (01) :91-110
[6]   Chalcones: A Valid Scaffold for Monoamine Oxidases Inhibitors [J].
Chimenti, Franco ;
Fioravanti, Rossella ;
Bolasco, Adriana ;
Chimenti, Paola ;
Secci, Daniela ;
Rossi, Francesca ;
Yanez, Matilde ;
Orallo, Francisco ;
Ortuso, Francesco ;
Alcaro, Stefano .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (09) :2818-2824
[7]  
Da Prada M, 1988, J Neural Transm Suppl, V26, P31
[8]   Structure and mechanism of monoamine oxidase [J].
Edmondson, DE ;
Mattevi, A ;
Binda, C ;
Li, M ;
Hubálek, F .
CURRENT MEDICINAL CHEMISTRY, 2004, 11 (15) :1983-1993
[9]   Monoamine oxidase-B inhibition in the treatment of Parkinson's disease [J].
Fernandez, Hubert H. ;
Chen, Jack J. .
PHARMACOTHERAPY, 2007, 27 (12) :174S-185S
[10]  
Finberg JPM, 1998, J NEURAL TRANSM-SUPP, P279